CTS Corp Q2 2026: Sales Climb 7%, Margins Reach Record, Guidance Lifted
CTS sits 78% above its 52-week low of $36.025.
Summary
CTS Corp posted Q2 2026 sales of $144.8M (+7% YoY) and record gross margins of 41.5%, while raising full-year guidance. Net earnings were $19.2M, impacted by a higher tax rate.
Key Events · Earnings and Guidance · CTS
-
Q2 Revenue and Margin Beat
Net sales rose 7% to $144.8 million, driven by 14.6% growth in diversified end markets. Gross margin hit a record 41.5%, up from 38.7% a year ago, reflecting favorable mix and operational improvements.
-
Full-Year Guidance Raised
CTS raised FY 2026 revenue guidance to $565–$585 million, up from prior outlook, citing strong demand in medical and industrial markets.
-
Tax Rate Headwind
Effective tax rate jumped to 27.0% from 19.4% due to valuation allowances against certain tax credits, limiting net earnings growth to 3.4% despite strong operating performance.
-
Strong Balance Sheet and Buybacks
Cash and equivalents stood at $107.5 million with $243.5 million available under the revolver. The company repurchased $3.5 million in shares during Q2, with $78.3 million remaining under its authorization.
Analysis · CTS · Manufacturing
A strong second quarter saw CTS Corporation lift sales 7% to $144.8 million while gross margins expanded to a record 41.5%. Net earnings edged up to $19.2 million, though a higher tax rate—driven by valuation allowances—tempered the advance. Reflecting confidence in sustained demand across medical and industrial markets, management raised full-year revenue guidance to $565–$585 million. The balance sheet remains sturdy with $107.5 million in cash and ample revolver capacity, and the buyback program continues with $78.3 million remaining. This quarter underscores the growth narrative and operational execution under new CEO Pratik Trivedi.
At the time of this filing, CTS was trading at $64.01 on NYSE in the Manufacturing sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $36.03 to $69.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.